THK-5351 tau-tracer uptake in patients with clinically diagnosed progressive supranuclear palsy
Objective: The objective of our study is to investigate characteristics of THK-5351 binding in patients with clinically diagnosed progressive supranuclear palsy (PSP) and correlate tau-tracer…Staging of cognitive impairment: Validation of a novel cognitive score with [18F]FDG-PET
Objective: To provide insight into the nature of cognitive deterioration and Parkinson's disease dementia (PDD) and to validate a novel cognitive score (also submitted for…Quantification of striatal dopamine transporters with [18F]PR04.MZ in patients with progressive supranuclear palsy and Parkinson’s disease
Objective: To evaluate the differences in striatal subregional dopamine transporter loss in Parkinson's disease (PD) and supranuclear palsy (PSP) and the diagnostic value of [18F]PR04.MZ…[18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer’s disease
Objective: To evaluate: (1) brain tau pathology in vivo in patients with Progressive Supranuclear Palsy (PSP) and Alzheimer's disease (AD); (2) whether brain tau pathology…The relationship between the cognitive phenotype and 5-HT2A receptor in PD with visual hallucinations
Objective: The aim of this study was to investigate the relationship between cognitive phenotype and 5-HT2A receptor availability in PD patients with visual hallucinations (VH).…PET imaging of tau pathology in progressive supranuclear palsy
Objective: This study aimed to determine whether there is an increase in [18F]-AV-1451 uptake in the brains of progressive supranuclear palsy (PSP) patients compared to…Depression, anxiety, and apathy in Parkinson’s disease: Insights from neuroimaging studies
Objective: (1) To evaluate the existing neuroimaging studies of depression, anxiety and apathy in Parkinson's disease (PD) and (2) to determine the key neural pathway…99mTc-TRODAT-1 SPECT findings in a patient with sporadic Creutzfeldt-Jakob disease
Objective: To report a case of sporadic CJD presenting insomnia,vertigo, ataxia and parkinsonism as first symptoms and describes the 99mTc-TRODAT-1 SPECT findings. Background: CJD is…Evaluation of the [ 99mTc] – TRODAT- 1 SPECT in the diagnosis of Parkinson’s disease and other movement disorders
Objective: Evaluation of the [ 99mTc] - TRODAT- 1 SPECT in the diagnosis of PD and other MD. Create a DATA bank for our population.…PET examination of the monoamine transporter with 11C-beta-CIT
Objective: To investigate the utility of 11C-β-CIT PET scan on Parkinson's disease diagnosis. Background: The monoamine reuptake sites transport dopamine, noradrenaline and serotonin from the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.